This entry was posted on November 20, 2008 at 9:28 pm and is filed under Amgen, VEGF.
You can follow any responses to this entry through the RSS 2.0 feed.
You can skip to the end and leave a response. Pinging is currently not allowed.
AZ’s Zactima Phase III data were released yesterday also, and seemed less than impressive to me (no numbers provided – but maybe they are embargoed for an upcoming conference?), with no statistical significance for the OS improvement endpoint.
I know, just headlines devoid of (free) analysis – but still, there are so many BMCL papers and industry announcements that if someone pre-reads them for me, it saves me from wadding through all that low-grade stuff. I found recently some BCML ASAP articles through KinaseCentral that could actually help us with a project.
What do any of these comments have to do with the article? Is this an “educated” website, or is everyone here to advertise and complain about unrelated topics? This article was supposed to be about Motesanib and no one even metions it once…
…and some people have a peanut allergy. Anyway, I hope that the corporate lawyers and other due-diligence imbeciles won’t harass you for KinasePro, and that you will have energy and time to continue writing about kinase compounds in the next year. Happy holiday!
You people really spend your time talking about and promoting small molecule kinase inhibitors? Highly selective, multi-target, blah, blah, blah. These compounds have killed more rats than Terminex. The highest concentrations of an orally administered kinase inhibitors are in the GI (mM) and the liver (uM)…they saturate the cytosol in the GI and other organs long before they ever make it to target tissue. Intestinal paralysis, elevated liver enzymes, organs swelling and shrinking. The whole kinase inhibitor thrust has been a quagmire. Our collections are now full of kinase inhibitors that have been a complete waste of chemistry resources.
gleevec might evade GI tox partially owing to the fact as a prodrug. its active metabolite is 3~5x more potent. it is curious that few people in the field paid much attent to the later. It could a way to go for future kianse inhibitors. btw sorafenib has 5x and 3x higher accumulation in liver and kidney comparing to blood. no wonder it got approved in hcc and rcc.